Toll Like Receptor 4 (hToll or CD284 or TLR4) – Pipeline Review, H1 2019

Global Markets Direct’s, ‘Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H1 2019’, provides in depth analysis on Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Gastrointestinal, Infectious Disease, Immunology, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Respiratory, Dermatology, Ear Nose Throat Disorders, Mouth and Dental Disorders, Musculoskeletal Disorders and Ophthalmology under development targeting Toll Like Receptor 4 (hToll or CD284 or TLR4).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)

- The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects

- The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AptaTargets SL

Batu Biologics Inc

Cyxone AB

Eisai Co Ltd

eTheRNA Immunotherapies NV

EyeGene Inc

GigaGen Inc

GlaxoSmithKline Plc

Harbor Therapeutics Inc

Immune Design Corp ...

AptaTargets SL

Batu Biologics Inc

Cyxone AB

Eisai Co Ltd

eTheRNA Immunotherapies NV

EyeGene Inc

GigaGen Inc

GlaxoSmithKline Plc

Harbor Therapeutics Inc

Immune Design Corp

Immunovo BV

NovImmune SA

TaiwanJ Pharmaceuticals Co Ltd

Takeda Pharmaceutical Co Ltd

Vascular Biogenics Ltd

Table of Contents

Table of Contents

Introduction

Toll Like Receptor 4 (hToll or CD284 or TLR4) – Overview

Toll Like Receptor 4 (hToll or CD284 or TLR4) – Therapeutics Development ...

Table of Contents

Introduction

Toll Like Receptor 4 (hToll or CD284 or TLR4) – Overview

Toll Like Receptor 4 (hToll or CD284 or TLR4) – Therapeutics Development

Toll Like Receptor 4 (hToll or CD284 or TLR4) – Therapeutics Assessment

Toll Like Receptor 4 (hToll or CD284 or TLR4) – Companies Involved in Therapeutics Development

Toll Like Receptor 4 (hToll or CD284 or TLR4) – Drug Profiles

Toll Like Receptor 4 (hToll or CD284 or TLR4) – Dormant Products

Toll Like Receptor 4 (hToll or CD284 or TLR4) – Discontinued Products

Toll Like Receptor 4 (hToll or CD284 or TLR4) – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Indications, H1 2019 (Contd..2), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1)

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Products under Development by Companies, H1 2019 (Contd..3), H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by AptaTargets SL, H1 2019

Pipeline by Batu Biologics Inc, H1 2019

Pipeline by Cyxone AB, H1 2019

Pipeline by Eisai Co Ltd, H1 2019

Pipeline by eTheRNA Immunotherapies NV, H1 2019

Pipeline by EyeGene Inc, H1 2019

Pipeline by GigaGen Inc, H1 2019

Pipeline by GlaxoSmithKline Plc, H1 2019

Pipeline by Harbor Therapeutics Inc, H1 2019

Pipeline by Immune Design Corp, H1 2019

Pipeline by Immunovo BV, H1 2019

Pipeline by NovImmune SA, H1 2019

Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2019

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Pipeline by Vascular Biogenics Ltd, H1 2019

Dormant Products, H1 2019

Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports